drugset
drugset / Trial / NCT05022849

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

NCT05022849 ↗

Phase 1 Completed 15 enrolled Janssen Research & Development, LLC
Non-randomizedSequentialOpen-labelOther

Summary

The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).

Timeline

Start
2021-09-28
Primary completion
2026-03-11
Completion
2026-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-75229414 Cell therapy — Intravenous
Background Abiraterone acetate Small molecule — Oral
Background Docetaxel Small molecule — Intravenous
Background Enzalutamide Other / unclassified — Oral

Indications

prostate neoplasm